tbuckley/cabot-search huggingface dataset:
Suspected Female-to-Male Sexual Transmission of Zika Virus — New York City, 2016
Authors: Alexander Davidson, Sally Slavinski, Kendra Komoto, Jennifer Rakeman, Don Weiss
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

A routine investigation by the New York City (NYC) Department of Health and Mental Hygiene (DOHMH) identified a nonpregnant woman in her twenties who reported she had engaged in a single event of condomless vaginal intercourse with a male partner the day she returned to NYC (day 0) from travel to an area with ongoing Zika virus transmission. She had headache and abdominal cramping while in the airport awaiting return to NYC. The following day (day 1) she developed fever, fatigue, a maculopapular rash, myalgia, arthralgia, back pain, swelling of the extremities, and numbness and tingling in her hands and feet. In addition, on day 1, the woman began menses that she described as heavier than usual. On day 3 she visited her primary care provider who obtained blood and urine specimens. Zika virus RNA was detected in both serum and urine by real-time reverse transcription-polymerase chain reaction (rRT-PCR) performed at the DOHMH Public Health Laboratory using a test based on an assay developed at CDC (1). The results of serum testing for anti-Zika virus immunoglobulin M (IgM) antibody performed by the New York State Department of Health Wadsworth Center laboratory was negative using the CDC Zika IgM antibody capture enzyme-linked immunosorbent assay (Zika MAC-ELISA) (2).
Urothelial carcinoma of the prostatic urethra: Long-term follow-up study.
Authors: Francesco Celestino, Cristian Verri, Francesco De Carlo, Germano Zampa, Vincenzo Pagliarulo, Francesco Masedu, Savino Mauro Di Stasi
Journal: Journal of Clinical Oncology (2015)

e15639 Background: The involvement of the prostatic urethra in high risk non muscle-invasive bladder cancer (NMIBC) varies between 10 to 40%. Treatment strategies and expected outcomes of this disease are not well defined. In a retrospective study, we look at the long-term outcomes in patients with urothelial carcinoma of the prostatic urethra (UCPU) concomitant with high risk NMIBC. Methods: From 1998 to 2010, 39 patients with high risk NMIBC and concomitant UCPU were recruited. After the initial transurethral resection (TUR) of all tumor visible on endoscopy and random cold-cup biopsies of the bladder and prostatic urethra, all patients underwent restaging TUR of the bladder and prostatic urethra 4–6 weeks later. Patients with non-muscle invasive UCPU (n = 33) underwent adjuvant intravesical BCG therapy, while patients with prostatic stromal or ductal invasion (n = 6) underwent neoadjuvant systemic chemotherapy and radical cystectomy. Patients with non-muscle invasive UCPU were followed-up with cystoscopy and urinary cytology every 3 months. A yearly CT scan was performed in all patients. The primary endpoint was disease-free interval. Analyses were done by intention to treat. Results: Median follow-up was 96 months (IQR 73-122). The median disease-free interval was 15 months (IQR 12-18) and 9 months (IQR 7-11) for UCPU and NMIBC, respectively; recurrence rate was 30% for UCPU and 38% for NMIBC; progression rate was 10.2% (4 patients) for UCPU and 17.9% (7 patients) for NMIBC; time to progression was 12 months (IQR 10-14) for UCPU and 9 (IQR 8-10) for NMIBC; overall and disease-specific survival rates for UCPU were 87.2% and 92.4% respectively. In patients with prostatic stromal or ductal invasion the disease free-interval was 8 months (IQR 7-9) and progression to metastatic disease was observed in 3/6 patients (50%). During the follow-up an upper urinary tract urothelial carcinoma was diagnosed in 6/39 patients (15.4%) Conclusions: TUR and adjuvant intravesical BCG therapy are effective treatments for UCPU. Radical cystectomy should be reserved as primary treatment in patients with stromal or ductal involvement. Strict follow-up of UCPU patients with concomitant NMIBC is mandatory to detect upper urinary tract tumors.
Cancer Theranostic Nanoparticles Self-Assembled from Amphiphilic Small Molecules with Equilibrium Shift-Induced Renal Clearance
Authors: Yuan Ma, Quanbing Mou, Mo Sun, Chunyang Yu, Jianqi Li, Xiaohua Huang, Xinyuan Zhu, Deyue Yan, Jian Shen
Journal: Theranostics (2016)

Nano drug delivery systems have emerged as promising candidates for cancer therapy, whereas their uncertainly complete elimination from the body within specific timescales restricts their clinical translation. Compared with hepatic clearance of nanoparticles, renal excretion of small molecules is preferred to minimize the agent-induced toxicity. Herein, we construct in vivo renal-clearable nanoparticles, which are self-assembled from amphiphilic small molecules holding the capabilities of magnetic resonance imaging (MRI) and chemotherapy. The assembled nanoparticles can accumulate in tumor tissues for their nano-characteristics, while the small molecules dismantled from the nanoparticles can be efficiently cleared by kidneys. The renal-clearable nanoparticles exhibit excellent tumor-inhibition performance as well as low side effects and negligible chronic toxicity. These results demonstrate a potential strategy for small molecular nano drug delivery systems with obvious anticancer effect and low-toxic metabolism pathway for clinical applications.
Systematic development of a a breast cancer survivorship program at a small independent oncology practice.
Authors: Cynthia Rogers, Shailesh R. Satpute
Journal: Journal of Clinical Oncology (2016)

52 Background: It is widely accepted that providing survivorship care plans leads to improvements in outcomes for cancer survivors. Treatment summaries are now part of ASCO and NCCN survivorship guidelines. We faced a unique challenge of implementing the survivorship care plan at the Jones Clinic as a small independent practice. The Jones Clinic consists of three full time physicians and two full time nurse practitioners. We see approximately 850 new patients per year. Methods: As a part of ASCO’s quality training program, we focused on the stage I – III (early stage) breast cancer patients who completed their initial therapy. We formed a team, identified the barriers, created a flow diagram of the process, assigned roles for each individual member and finally implemented the process. Results: The major issues identified were lack of provision in the electronic medical record (EMR) system for survivorship and lack of standardized data entry process. We created a system in the EMR for survivorship data entry and extraction of such data in a document. Since July 2015, one hundred percent of breast cancer patients completing adjuvant therapy at the Jones Clinic have received a survivorship treatment summary and a plan of care. The care plan is also shared with their primary care provider. Importantly, creating a survivorship document required less than 10 minutes of the provider’s time. Conclusions: We are now able to provide our patients with a survivorship care plan and address survivorship issues within thirty days of completion of therapy. Creating the care plan requires minimal time from the providers. Our new process meets ASCO guidelines for survivorship care plans and no additional staffing was needed. We now plan to provide a survivorship care plan to all oncology patients treated with curative intent.
NLRC5, a promising new entry in tumor immunology
Authors: Sonia T. Chelbi, Greta Guarda
Journal: Journal for ImmunoTherapy of Cancer (2016)

The recent use of T cell-based cancer immunotherapies, such as adoptive T-cell transfer and checkpoint blockade, yields increasing clinical benefit to patients with different cancer types. However, decrease of MHC class I expression is a common mechanism transformed cells take advantage of to evade CD8(+) T cell-mediated antitumor responses, negatively impacting on the outcome of immunotherapies. Hence, there is an urgent need to develop novel approaches to overcome this limitation. NLRC5 has been recently described as a key transcriptional regulator controlling expression of MHC class I molecules. In this commentary, we summarize and put into perspective a study by Rodriguez and colleagues recently published in Oncoimmunology, addressing the role of NLRC5 in melanoma. The authors demonstrate that NLRC5 overexpression in B16 melanoma allows to recover MHC class I expression, rising tumor immunogenicity and counteracting immune evasion. Possible ways of manipulating NLRC5 activity in tumors will be discussed. Highlighting the therapeutic potential of modulating NLRC5 levels, this publication also encourages evaluation of NLRC5, and by extension MHC class I pathway, as clinical biomarker to select personalized immunotherapeutic strategies.
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial
Authors: M. Früh, H.B. Ris, A. Xyrafas, S. Peters, R.O. Mirimanoff, O. Gautschi, M. Pless, R. Stupp
Journal: Annals of Oncology (2016)
Non-Intensive but Constant and Exhausting Action on the Leukemic Clone Is a Reasonable and Effective Treatment Approach in Adult Acute Lymphoblastic Leukemia: Results of the Russian Acute Lymphoblastic Leukemia (RALL) Study Group
Authors: Elena N. Parovichnikova, Vera Troitskaya, Andrey N Sokolov, Galina Klyasova, Larisa A Kuzmina, Sergey K. Kravchenko, Elena O. Gribanova, Sergey N Bondarenko, Olga Yu Baranova, Tatiana Kaporskaya, T Ryltzova, Tamara Pavlovna Zagoskina, E Zinina, Olga Samoilova, Alfiya Nizamutdinova, A Klimovich, E Karyakina, A Eluferieva, L Gavrilova, T Konstantinova, N Vopilina, Valeri Lapin, Alexander Pristupa, T Tikunova, Zalina Akhmerzaeva, Tatiana Obukhova, Mikhail Rusinov, Sergey M. Kulikov, Valeri G Savchenko
Journal: Blood (2014)
Lung ultrasonography for assessment of oxygenation response to prone position ventilation in ARDS
Authors: Malik Haddam, Laurent Zieleskiewicz, Sebastien Perbet, Alice Baldovini, Christophe Guervilly, Charlotte Arbelot, Alexandre Noel, Coralie Vigne, Emmanuelle Hammad, François Antonini, Samuel Lehingue, Eric Peytel, Qin Lu, Belaid Bouhemad, Jean-Louis Golmard, Olivier Langeron, Claude Martin, Laurent Muller, Jean-Jacques Rouby, Jean-Michel Constantin, Laurent Papazian, Marc Leone
Journal: Intensive Care Medicine (2016)
Epidemiological status of BSE in France – update on ‘born after the ban’ cases
Authors: C Ducrot, D Calavas, T Baron, A  E Agrech, M Coudert, M Savey
Journal: Eurosurveillance (2000)

Despite measures taken in France since 1990 to control the spread of bovine spongiform encephalopathy (BSE), the incidence of BSE cases notified in France by the BSE Epidemiological Surveillance Network has been rising in recent years. By 1 July 2000, 103
Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants
Authors: Elodie Belnoue, Wilma Di Berardino-Besson, Hubert Gaertner, Susanna Carboni, Isabelle Dunand-Sauthier, Fabrice Cerini, Else-Marit Suso-Inderberg, Sébastien Wälchli, Stéphane König, Andres M Salazar, Oliver Hartley, Pierre-Yves Dietrich, Paul R Walker, Madiha Derouazi
Journal: Molecular Therapy (2016)

Cell penetrating peptides (CPPs) from the protein ZEBRA are promising candidates to exploit in therapeutic cancer vaccines, since they can transport antigenic cargos into dendritic cells and induce tumor-specific T cells. Employing CPPs for a given cancer indication will require engineering to include relevant tumor-associated epitopes, administration with an appropriate adjuvant, and testing for antitumor immunity. We assessed the importance of structural characteristics, efficiency of in vitro transduction of target cells, and choice of adjuvant in inducing the two key elements in antitumor immunity, CD4 and CD8 T cells, as well as control of tumor growth in vivo. Structural characteristics associated with CPP function varied according to CPP truncations and cargo epitope composition, and correlated with in vitro transduction efficiency. However, subsequent in vivo capacity to induce CD4 and CD8 T cells was not always predicted by in vitro results. We determined that the critical parameter for in vivo efficacy using aggressive mouse tumor models was the choice of adjuvant. Optimal pairing of a particular ZEBRA-CPP sequence and antigenic cargo together with adjuvant induced potent antitumor immunity. Our results highlight the irreplaceable role of in vivo testing of novel vaccine constructs together with adjuvants to select combinations for further development.
Update in Tuberculosis/Pulmonary Infections 2015
Authors: Serena P. Koenig, Jennifer Furin
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

The year 2015 included both innovations and setbacks in mycobacterial lung disease, especially tuberculosis (TB).In November, the World Health Organization (WHO) announced that TB is once again the leading infectious killer of adults globally, and there remain serious diagnostic and treatment gaps (1).At the same time, there are exciting new developments in diagnostics for latent and active TB disease and in medical therapy, especially for persons with drug-resistant disease.In addition, real progress is being made in diagnosing and treating other forms of mycobacterial lung disease.Many of these important developments have been reported in the Journal.We summarize these findings here, with a focus on TB immunology, diagnosis of latent and active disease, TB prevention, and TB treatment.Finally, we present updates in nontuberculous mycobacterial lung disease. TB ImmunologyUnderstanding the immune response to Mycobacterium tuberculosis is important, given that although more than 2 billion individuals are infected with the bacteria, only a fraction of them go on to become sick.Furthermore, such an understanding is essential for developing a successful TB vaccine.The complex interaction between the pathogen and the human immune system was the topic of a paper by Mehra and colleagues who looked at the role of the DosR regulon in a TB model in macaques (2).DosR regulates the response of M. tuberculosis to hypoxia and appears to have an important role in modulating immune responses to the bacteria (3).In their study, the team of investigators evaluated strains of M. tuberculosis that had mutations in the DosR region and found that although mutant strains could initially replicate, they did not cause disease in the monkey model, whereas strains with complemented DosR regulons were able to cause both infection and disease.They conclude that the complemented DosR regulon modulates both the magnitude and the timing of adaptive immunity and is associated with persistent infection.The study has important implications not only for better understanding the different immune responses M. tuberculosis evokes in its human hosts but also for better targeting responses that could lead to an effective TB vaccine.
Haploinsufficiency of MeCP2-interacting transcriptional co-repressor SIN3A causes mild intellectual disability by affecting the development of cortical integrity
Authors: Josefine S Witteveen, Marjolein H Willemsen, Thaís C D Dombroski, Nick H M van Bakel, Willy M Nillesen, Josephus A van Hulten, Eric J R Jansen, Dave Verkaik, Hermine E Veenstra-Knol, Conny M A van Ravenswaaij-Arts, Jolien S Klein Wassink-Ruiter, Marie Vincent, Albert David, Cedric Le Caignec, Jolanda Schieving, Christian Gilissen, Nicola Foulds, Patrick Rump, Tim Strom, Kirsten Cremer, Alexander M Zink, Hartmut Engels, Sonja A de Munnik, Jasper E Visser, Han G Brunner, Gerard J M Martens, Rolph Pfundt, Tjitske Kleefstra, Sharon M Kolk
Journal: Nature Genetics (2016)
P-261 Survival and disease-free survival in a consecutive monocentric series of more than 1000 D-2 gastric resection for cancer
Authors: A. Chiappa, E. Bertani, N. Fazio, D. Foschi, F. Luca, M. Venturino, C. Ferrari, I. Monsellato, S. Galdy, D. Ravizza, M. Tulli, R. Biffi
Journal: Annals of Oncology (2016)
Abstract 17574: Drp1-dependent Mitochondrial Autophagy Plays A Protective Role In Response To Pressure Overload Induced Mitochondrial Dysfunction And Heart Failure
Authors: Akihiro Shirakabe, Yoshiyuki Ikeda, Peiyong Zai, Toshiro Saito, Junichi Sadoshima
Journal: Circulation (2015)

Dynamin-related protein 1 (Drp1) plays an essential role in maintaining mitochondrial (Mt) quality control through Mt fission and mitophagy. We investigated how Mt function, mitophagy and Drp1 are regulated in the heart during pressure overload (PO) and their roles in regulating cardiac function. Mice were subjected to transverse aortic constriction (TAC) for 1, 3, 5, 7, 14 and 30 days. Left ventricular (LV) weight/tibial length (LVW/TL) was significantly elevated at Day 5 (TAC vs sham; 6.21 ± 0.10 vs 4.59 ± 0.10, p&lt;0.05). Ejection fraction (EF) was maintained at Day 7 (82.1±3.4 vs 78.4±3.2%), but gradually decreased thereafter (at Day 30, 51.0±4.5, p&lt;0.05). Both Mt ATP content (-65.0%, p&lt;0.05) and production (-32.0%, p&lt;0.05) were reduced significantly at Day 7 and thereafter. Mt mass, evaluated by electron microscopy (EM), was reduced (-30.0%, p&lt;0.05) transiently at Day 5. Drp1 was phosphorylated at S616 and accumulated in mitochondria, peaking at Day 3. In EM analyses, autophagosomes containing mitochondria were observed at Day 5 and 7, but not at other time points. Mt DNA content was also transiently decreased below control levels at Day 3 and 5. The levels of COX I and COX IV, Mt matrix proteins, were decreased significantly at Day 3, 5 and 7 compared to sham. These results suggest that PO induces Drp1 translocation and Mt autophagy only transiently around Day 3-7, and that mitochondrial dysfunction develops thereafter. PO-induced decreases in EF (58.2± 6.2 vs 82.2 ± 1.0%, p&lt;0.05), and increases in LVW/TL (6.43 ± 0.82 vs 5.16 ± 0.47, p&lt;0.05) and lung weight/TL (13.31 ± 0.63 vs 7.01 ± 0.66, p&lt;0.05) were all exacerbated in cardiac-specific heterozygous Drp1 knock out (Drp-hetCKO) mice compared to in control mice. Mt mass was significantly greater (1.21 ± 0.46 vs 1.00 ± 0.02, p&lt;0.05) and Mt ATP production was significantly lower (0.58 ± 0.05 vs 1.00 ± 0.02, p&lt;0.05) in Drp-hetCKO than in control mice, indicating accumulation of dysfunctional mitochondria in Drp-hetCKO mice. Although PO transiently induces Mt translocation of Drp1 and Mt autophagy, Mt dysfunction eventually develops, followed by development of heart failure. Endogenous Drp1 protects the heart from failure during PO by inducing degradation of damaged mitochondria.
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in<i>BRAF</i>-Mutated Colorectal Cancer
Authors: Filippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, Emanuele Valtorta, Rosa Berenato, Ludovic Barault, Marta Caporale, Adele Busico, Federica Morano, Ambra Vittoria Gualeni, Alessandra Alessi, Giulia Siravegna, Federica Perrone, Maria Di Bartolomeo, Alberto Bardelli, Filippo de Braud, Federica Di Nicolantonio
Journal: Cancer Discovery (2016)

A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with panitumumab plus vemurafenib. Pre-existing cells with increased MET gene copy number in the archival tumor tissue likely underwent clonal expansion during treatment, leading to the emergence of MET amplification in the rebiopsy taken at progression. In BRAF-mutated colorectal cancer cells, ectopic expression of MET conferred resistance to panitumumab and vemurafenib, which was overcome by combining BRAF and MET inhibition. Based on tumor genotyping and functional in vitro data, the patient was treated with the dual ALK-MET inhibitor crizotinib plus vemurafenib, thus switching to dual MET and BRAF blockade, with rapid and marked effectiveness of such strategy. Although acquired resistance is a major limitation to the clinical efficacy of anticancer agents, the identification of molecular targets emerging during the first treatment may afford the opportunity to design the next line of targeted therapies, maximizing patient benefit.MET amplification is here identified-clinically and preclinically-as a new mechanism of resistance to EGFR and BRAF dual/triple block combinations in BRAF-mutated colorectal cancer. Switching from EGFR to MET inhibition, while maintaining BRAF inhibition, resulted in clinical benefit after the occurrence of MET-driven acquired resistance. Cancer Discov; 6(9); 963-71. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 932.
High-dose therapy: here to stay or just visiting?
Authors: G P Canellos
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.1.5 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8270983 High-dose therapy: here to stay or just visiting? G P CanellosxG P CanellosSearch for articles by this author https://doi.org/10.1200/JCO.1994.12.1.5 PDF "High-dose therapy: here to stay or just visiting?." Journal of Clinical Oncology, 12(1), pp. 5–6© 1994 by American Society of Clinical Oncology
Cholesteatoma
Authors: N W Todd
Journal: New England Journal of Medicine (1994)

Figure 1 Cholesteatoma. A cholesteatoma medial to an intact translucent tympanic membrane is shown in the left ear of a five-year-old girl. This abnormality was found by an audiologist during screening at school. The tympanic membrane was illuminated with a tungsten lamp and photographed through a Hopkins rod mounted on a 35-mm camera with Fuji 1600 film. The color was corrected to a reference standard during processing. Figure 1 Cholesteatoma. A cholesteatoma medial to an intact translucent tympanic membrane is shown in the left ear of a five-year-old girl. This abnormality was found by an audiologist during screening at school. The tympanic membrane was illuminated with a tungsten lamp and photographed through a Hopkins rod mounted on a 35-mm camera with Fuji 1600 film. The color was corrected to a reference standard during processing. N. Wendell Todd, M.D.Emory University, Atlanta, GA 30322
Abstract 2307: Rate of Progression of Electrocardiographic Conduction Disease in Myotonic Dystrophy Type 1 Patients
Authors: Mohammad Marashdeh, Miriam Lowe, Abeer Alqaisi, William Groh
Journal: Circulation (2006)

Background: Myotonic Dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disorder with cardiac involvement including conduction disease, arrhythmias, and sudden death (SD). The severity o...
Was the increase in culture-confirmed Campylobacter infections in Denmark during the 1990s a surveillance artefact?
Authors: Hanne D Emborg, Peter Teunis, Jacob Simonsen, Karen A Krogfelt, Charlotte S Jørgensen, Johanna Takkinen, Kåre Mølbak
Journal: Eurosurveillance (2015)

In 1991, 1999 and 2006, randomly selected individuals from the Danish Central Personal Register provided a serum sample. From individuals aged 30 years and above, 500 samples from each year were analysed for Campylobacter IgG, IgA and IgM antibodies using a direct ELISA method. We applied a seroincidence calculator available from the European Centre for Disease Prevention and Control to perform a mathematical back-calculation to estimate the annual Campylobacter seroincidence in the Danish population. The estimated Campylobacter seroincidence did not differ significantly between the 1991, 1999 and 2006 studies although the reported number of culture-confirmed cases of Campylobacter infection increased 2.5 fold from 1993 to 1999 among individuals aged 30 years and above. This suggests that Campylobacter was widely present in the Danish population before the increase in poultry-associated clinical Campylobacter infections observed from 1993 to 2001 among individuals of this age groups.
High Risk Apml Treated Successfully with Four Cycles of ATO and ATRA Combination in Resource Constrained Settings
Authors: Subhash Varma, Uday Yanamandra, Alka Khadwal, Gaurav Prakash, Vikas Suri, Savita Kumari, Parathan Karunakaran, Shano Naseem, Reena Das, Neelam Varma, Pankaj Malhotra
Journal: Blood (2015)